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Blocking of angiotensin II  
is more than blocking of 
transforming growth factor-β
Christoph Daniel1
Fibrosis is a common feature of chronic kidney diseases that is 
mediated by matrix-producing myofibroblasts. One potential origin 
of myofibroblasts is epithelial–mesenchymal transition (EMT) of 
tubuloepithelial cells. Transforming growth factor-β (TGF-β) is a key 
factor inducing EMT. Carvajal et al. demonstrate that angiotensin II 
induces EMT by classical stimulation of TGF-β and also by a TGF-β- 
independent pathway, both signaling via Smad molecules. Therefore, 
blockade of angiotensin II is more than lowering of blood pressure and 
inhibition of TGF-β stimulation.
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Chronic kidney diseases are emerging 
as a worldwide public-health problem. 
Recent reports suggest that up to 10% of 
the population may be affected by chronic 
kidney disease (CKD).1 Irrespective of the 
underlying cause, CKD is linked with the 
development of glomerulosclerosis and 
tubulointerstitial fibrosis, which is the 
major cause of end-stage renal disease in 
humans. Fibrosis is characterized by accu-
mulation of matrix molecules such as colla-
gens and fibronectin due to overexpression 
and decreased clearing and degradation of 
these matrix components. The key cellular 
mediator of fibrosis is the myofibroblast, 
which, when activated, serves as the pri-
mary collagen-producing cell.2 In addition 
to activated local tissue fibroblasts, myofi-
broblasts can originate from circulating 
mesenchymal progenitors or from epithe-
lial cells in a process known as epithelial–
mesenchymal transition (EMT).2 The 
process of EMT includes disaggregation 
of epithelial units and reshaping of epi-
thelia for movement. During transition, 
epithelial cells lose polarity, adherens 
junctions, tight junctions, desmosomes, 
and cytokeratin intermediate filaments in 
order to rearrange their F-actin stress fibers 
and express filopodia and lamellopodia.3 
Molecular markers of this transition proc-
ess are, for example, increased expression 
of vimentin and α-smooth muscle actin 
and loss of E-cadherin expression.3 Dif-
ferent cytokines and metalloproteinases 
have been identified as being involved in 
the induction of EMT. One key player for 
EMT induction is transforming growth 
factor-β (TGF-β). TGF-β promotes EMT 
by several mechanisms, but the Smad path-
way is the most relevant. Additionally, the 
renin–angiotensin–aldosterone system is 
a known modulator of renal fibrosis. It is 
well accepted that angiotensin II (Ang II) 
induces TGF-β, but less is known about 
potential TGF–β-independent actions of 
Ang II on fibrosis and EMT. The article by 
Carvajal and co-workers4 (this issue) elu-
cidates an additional role of Ang II in the 
induction of EMT besides its effects medi-
ated by TGF-β.
This group showed that stimulatory 
effects of Ang II-induced EMT can be 
divided in two phases, an early, acute 
TGF-β–independent and a late TGF-β–
dependent phase. Ang II phosphorylated 
tubuloepithelial Smad2 and Smad3 as early 
as 24 hours after infusion in rats. At this 
time point after Ang II infusion, neither 
TGF-β nor the potential TGF-β activator 
thrombospondin 1 was increased, sug-
gesting that Smad2/3 phosphorylation is 
TGF-β independent (Figure 1). In Ang II 
stimulation experiments using cultured 
human tubuloepithelial cells, the authors 
confirmed that Ang II rapidly activates the 
Smad pathway by a TGF-β–independent 
mechanism using TGF-β–neutralizing 
antibody or a TGF-β receptor blocker. Spe-
cific blockade of p38–mitogen-activated 
protein kinase (p38-MAPK), extracellu-
lar signal-regulated kinase-1/2 (ERK1/2), 
and Jun kinase during Ang II stimulation 
revealed that all three kinases are involved 
in early activation of the Smad pathway.
This mechanism of TGF-β–independent 
Smad2 and Smad3 activation by Ang II 
is not restricted to the kidney. Recent 
studies using vascular smooth muscle 
cells (VSMCs) also demonstrated TGF-
β–independent Smad activation mediated 
by MAPK,5,6 suggesting that this pathway 
is used in cells of different organs. Interest-
ingly, Smad phosphorylation in VSMCs was 
mediated by p385 or ERK1/2.6 Although 
both Smad2 and Smad3 were activated by 
Ang II by a TGF-β–independent mecha-
nism, only phosphorylation of Smad3 was 
found to be important for upregulation of 
collagen I in VSMCs, as was demonstrated 
by the use of VSMCs defective in either 
Smad2 or Smad3.6 For tubuloepithelial cells 
it is not known whether Smad2, Smad3, 
or both are required for the induction 
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of EMT and fibrosis. Overexpression of 
Smad7 inhibited Ang II-induced vimentin 
expression, confirming that activation of 
Smad2/3 is necessary for Ang II-mediated 
EMT. Experiments using losartan showed 
that Ang II-induced EMT is mediated by 
the angiotensin receptor type 1.
The late phase of Ang II-mediated 
EMT was TGF-β dependent and could 
be detected 72 hours after stimulation 
with Ang II with the use of cultured 
tubulo epithelial cells. In vivo, the TGF-
β–dependent pathway seems to be initiated 
later. Three days after Ang II infusion, only 
TGF-β mRNA, not protein, was upregu-
lated by Ang II infusion. In contrast, TGF-β 
expression was markedly increased 14 days 
after the start of Ang II infusion, indicating 
that Smad2/3 phosphorylation observed on 
days 1 and 3 was TGF-β independent.
The work using cultured tubular cells 
could not show TGF-β–independent 
action of Ang II on vimentin expression 
lasting longer than 2 days, which suggests 
that TGF-β–independent EMT induc-
tion may be reversible. Furthermore, 
α-smooth muscle actin, as a marker for 
myofibro blasts, was not induced during 
early TGF-β–independent Ang II-medi-
ated EMT. Therefore, initiation of Ang II-
mediated EMT seems to be mediated by a 
TGF-β–independent process, but progres-
sive EMT needs TGF-β. EMT induction 
in tubuloepithelial cells is mediated by the 
TGF-β downstream effector connective tis-
sue growth factor (CTGF), since CTGF anti-
sense oligonucleotides effectively diminish 
Ang II-induced EMT.7 Nevertheless, both 
pathways, TGF-β–dependent and –inde-
pendent Smad activation, should be possible 
in vivo. However, chronic kidney diseases 
are slowly progressive processes. Since diag-
nosis of kidney diseases and subsequent ini-
tiation of treatment with therapeutics often 
occur when disease is still established, the 
impact of the TGF-β–independent mecha-
nism in vivo is unclear.
The article by Carvajal and colleagues4 
gives new insights into mechanisms of 
EMT induction by Ang II. These results 
promote the use of Ang II blockers such as 
angiotensin-converting enzyme inhibitors 
or angiotensin receptor type 1 blockers for 
therapy of kidney diseases associated with 
fibrosis. Ang II-blocking strategies using 
either angiotensin-converting enzyme 
blockers or Ang II receptor blockers are 
one of the most effective therapies used to 
target kidney fibrosis in humans, exerting 
their renoprotective effects by different 
mechanisms: lowering the blood pressure 
and inhibiting profibrotic effects mediated 
by Ang II. Therefore these drugs showed 
additional antifibrotic effects as compared 
with antihypertensive drugs such as beta-
blockers and calcium channel blockers.8 
Interventions inhibiting the activity of the 
renin–angiotensin–aldosterone system 
may slow or even halt the progression of 
chronic nephropathies,9 but they are not 
able to prevent CKD. Ang II seems to be 
one important factor, but not the only one, 
involved in EMT and renal fibrosis. The 
development of new antifibrotic therapies 
is needed. TGF-β, the known profibrotic 
key factor, is induced by Ang II, but also 
by many other mechanisms. Therefore, 
TGF-β–blocking strategies could also be 
effective in the treatment of renal fibrosis 
and CKD.10 In addition, besides Ang II 
and TGF-β, there are many other mecha-
nisms known to activate myofibroblasts, 
including paracrine signals derived from 
lymphocytes and macrophages, autocrine 
factors secreted by myofibroblasts, and 
pathogen-associated molecular patterns 
produced by pathogenic organisms that 
interact with pattern recognition recep-
tors on fibroblasts. Cytokines, chemokines, 
angiogenic factors, growth factors, per-
oxisome proliferator-activated receptors, 
acute-phase proteins, and caspases have 
also been identified as important regula-
tors of fibrosis and are being investigated 
as potential targets of antifibrotic drugs.2 
Better understanding of key mechanisms 
involved in renal repair and fibrosis is 
needed to develop more effective drugs to 
treat CKD in the future.
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figure 1 | Pathways of Ang II-mediated fibrosis induction. Ang II-induced EMT, shown as 
increased expression of vimentin and α-smooth muscle actin and downregulation of E-cadherin, is 
mediated by phosphorylation of Smad2/3, which can be inhibited by Smad7. Early Ang II-induced 
EMT was mediated by a TGF-β-independent pathway using the angiotensin receptor type 1 (AT1 
receptor) and mitogen-activated protein kinases (MAPK) (dashed lines). In contrast, late Ang 
II-induced EMT was TGF-β dependent (solid lines). 
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Multiple effects of HMG-CoA 
reductase inhibitors (statins) 
besides their lipid-lowering function
Bettina Haslinger-Löffler1
The paper by Sharyo et al. shows that statins reduce the severity in a 
model of renal–ischemia reperfusion injury and raises the therapeutic 
possibility of using statins as pharmacological intervention against acute 
kidney injury. This, together with previous studies, indicates that statins 
exert a wide spectrum of anti-inflammatory, immunomodulatory, and 
protective effects besides their lipid-lowering function.
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Inhibitors of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase (stat-
ins) have become the most widely used 
drugs for lowering serum cholesterol levels, 
applied to at least 15% of patients admitted 
to hospitals.1 They are mainly used for pre-
vention of cardiovascular events, and they 
have proved to be highly effective. How-
ever, clinical studies demonstrated that the 
statin-mediated lowering of cholesterol 
and triglycerides appeared to account for 
many but not all of the beneficial effects 
in cardiovascular diseases.2 Furthermore, 
statins improve the outcome of vascular 
diseases, some of which are not associated 
with elevated lipid levels—for example, 
stroke and transplantation-associated 
coronary vasculopathy.2,3 These observa-
tions led to the hypothesis that statins do 
not only improve the lipid profile but also 
have direct vascular and tissue-protective 
actions. In this regard, Sharyo et al.4 (this 
issue) demonstrated in a renal ischemia–
reperfusion injury mouse model that 
pravastatin ameliorated renal function 
and injury independent of plasma cho-
lesterol levels. They also report that prav-
astatin prevented the increase in plasma 
interleukin-6 levels induced by ischemic 
kidney injury.4 As interleukin-6 is an 
important regulator of acute inflammatory 
reactions, these findings are in line with 
many other published works demonstrat-
ing anti-inflammatory actions of statins.2 
Especially in vitro studies with different cell 
types support lipid-lowering–independent 
functions of statins: It has been shown 
that statins can interfere with leukocyte–
endothelial interactions and prevent the 
adhesion and migration of leukocytes to 
the inflammatory side. As Sharyo et al.4 
mention, simvastatin can bind directly to 
leukocyte function antigen-1 (LFA-1) and 
inhibit leukocyte adhesion.5 This function 
is completely independent of blocking the 
activity of HMG-CoA reductase and lipid 
lowering (Figure 1). Additionally, statins 
were found to diminish the expression of 
various cytokines, such as interleukin-6 or 
tumor necrosis factor-α, in macrophages. 
But also in non-professional phagocytes, 
for example, endothelial cells and smooth 
muscle cells, the expression of chemotac-
tic and proinflammatory mediators, such 
as monocyte chemoattractant protein-1 
and interleukin-8, could be reduced by the 
use of statins.2 Furthermore, statins have 
been shown to interfere with the genera-
tion of reactive oxygen species or to acti-
vate scavenging systems for free radicals, 
such as the thioredoxin system. Especially 
with regard to the vascular system, many 
additional proangiogenic and protective 
properties of statins have been reported, 
including many beneficial effects on re-
endothelialization following vessel injury 
and inhibition of platelet aggregation in 
diseased vessel walls.2,6 Because of the 
diverse anti-inflammatory and vasopro-
tective properties, it was suggested to use 
statins not only for the treatment of vas-
cular diseases but also in infected or septic 
patients. Recent work even demonstrated 
antimicrobial actions of statins.7
Inflammatory processes, especially the 
release of proinflammatory cytokines, 
essentially regulate tissue remodeling and 
wound healing. The formation and deposi-
tion of fibrin is part of the hemostatic proc-
ess in response to inflammation and tissue 
injury. However, when the fibrin is not 
removed because of an insufficient fibrino-
lytic activity, it becomes organized. This can 
result in fibrous tissue remodeling with loss 
of organ function. In different cell types, 
including endothelial cells, smooth mus-
cle cells, and proximal tubular cells, statins 
efficiently promote the fibrinolytic activity 
by diminishing the expression of plasmino-
gen activator inhibitor-1 and of the proco-
agulant tissue factor and by enhancing that 
of tissue-type plasminogen activator.2,8,9 In 
this way statins might help to remove fibrin 
deposits and recover organ function. Fur-
thermore, statins are supposed to interfere 
with matrix turnover. The breakdown of 
matrix is essentially mediated by a family 
